TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Percent Change in Total Bone Mineral Density (BMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Eradication success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in cardiac repolarization (QTci)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of patients who consented to biobanking
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Dental sensitivity intensity change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain neuroplasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reaching kinematics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fine motor function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily use of affected hand
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: RDI for each EC chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chemotherapeutic dose adjustment due to neutropenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Overall completion rate of chemotherapy
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Number of Evaluable Patients Alive at 6 Months
Endpoint domain: Mortality/survival
Primary endpoint: Change in total disease activity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of extremely skewed X chromosome inactivation (SXCI > 90%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HBsAg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sensitivity and specificity of EarlyTect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor Immune-Related Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: rate of intra abdominal infections
Endpoint domain: Adverse events/effects
Primary endpoint: Change in the VISA-A questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: No evidence of hemorrhage or vessel exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time to return to full participation in sports
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change From Baseline on the Delis-Kaplan Executive Function System
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change From Baseline on the Bruininks-Oseretsky Test of Motor Development - 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Physical functioning
Primary endpoint: Change From Baseline on the Conners Parent Rating Scales: DSM Attention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change from baseline in maximal exercise capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impairment by the premenstrual syndrome
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improvement in Chronic Low Grade Non Hematologic Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change of 3-hour Mean Area Under the Curve (AUC) of C-peptide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Percent Regurgitation-Free Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of lung metastasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: rate of tumor recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: AUC (0 - Inf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CST 1/2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily Minutes of Physical Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minutes of Light to Moderate Physical Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Patients With a Modified Rankin Scale Score of 0-1
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Study Retention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Session Attendance
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rate of non-progression after 3 months of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Maximum percent decline in calculated creatinine clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change of DSM-5 criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of disabilities caused by the problematic Internet use
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change of negative consequences caused by the problematic Internet use
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of omega 3 PUFA supplementation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence and severity of delirium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Refractive changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in self-injury attentional bias
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of erectile dysfunction after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Penile complications
Endpoint domain: Adverse events/effects
Primary endpoint: Presence of Catheter-Related Bloodstream Infection (CRBSI)
Endpoint domain: Adverse events/effects
Primary endpoint: Plaque index of Silness and Loe
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiographic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Complicated clinical course
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Urine Drug Screens
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Substance Use and Problems
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from baseline on the Neck Disability Index (NDI)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change from Baseline in Clinician-Administered Dissociative States Scale (CADSS) Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with Vital Sign Abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Continuous Paired Associate Learning Test (cPALT) Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Morphologic changes in the retina
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contrast Sensitivity Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Yield of histologically interpretable specimens
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Treatment Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30 Day Survival Rate
Endpoint domain: Mortality/survival
Primary endpoint: Change From Baseline in Pulmonary Vascular Resistance (PVR) at 24 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Identification of baseline vaginal microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of baseline urinary tract microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of key biomarkers associated with risk of postoperative urinary tract infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 28th day mortality rate
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of adverse events as defined as DLTs
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Tolerated Dose (MTD) of NeoTCR-P1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Proportion of subjects with remission maintained
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Risk of developing lymphoma
Endpoint domain: Mortality/survival
Primary endpoint: Occurrence of solicited symptoms during 4 days following vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of unsolicited symptoms during the 31 days following vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Evidence of clinically definite ischemic stroke
Endpoint domain: Mortality/survival
Primary endpoint: Sensory and affective dimensions of dyspnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rad-67 Sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rad-67 Specificity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of Re-ruptures
Endpoint domain: Adverse events/effects
Primary endpoint: Skin Picking Scale Change
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean change in Physical Performance Assessment in Stroke (PPAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to mobile technologies for self-monitoring
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Ratings of Job Application Quality
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Ratings of Job Interview Performance
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Objective Observation of Workplace Productivity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Inattentive/Overactive Rating
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Migration pattern greater than 0.2mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Circulating Malondialdehyde Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Circulating F2-isoprostane Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Flow-mediated Dilation (FMD) of the Brachial Artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction of surface of allodynia area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Anogenital distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Silent breast cancer prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Freedom From Left Ventricular Lead-related Complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Successful Left Ventricular Lead Implants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Left Ventricular Bipolar Pacing Capture Threshold (Volts)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: change in NTproBNP plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: severity of congestive heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Beneficial bacteria level in stool
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mass balance after a single intravenous (IV) dose of [14C]NXL104 from urine excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total radioactivity concentrations in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total radioactivity levels in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mass balance after a single intravenous (IV) dose of [14C]NXL104 from faeces excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total radioactivity concentrations in faeces
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first occurrence of hospitalization for acute myocardial infarction, unstable angina pectoris or ischemic stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Presence of contamination on clothing, skin, or hair
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in mean mitral valve gradient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Frequency of involuntary leakage of urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Differences in sleep phenotypes
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Differences in Gut Microbiome Diversity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in vivo 13C-Spirulina GEBT response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: UCLA PTSD-I score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Degree of foramen magnum stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evolution by radiological clinical data
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seizure rate reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Serum non-phosphorylated, non-carboxylated Matrix Gla Protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage contribution of DHA to total phospholipid fatty acids in cord blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Protein biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence rate of endometriosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Timely delivered proportion
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of days the patients treated
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of patients who developed AEs/SAEs related to BCD-132
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients who developed Grade 3-4 AEs related to BCD-132
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients who discontinued the study due to AEs/SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects diagnosed with colonic adenoma, advanced adenoma or cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Improvement of at Least 2 Grades in ISGA Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in Inflammatory Lesion Counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in Non-inflammatory Lesion Counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in Total Lesion Counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Non-serious AEs (Non-SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Adverse Event of Special Interests (AESIs)
Endpoint domain: Adverse events/effects
Primary endpoint: PTSD checklist
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Hamilton Depression Inventory
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pathologic Complete Response Rate (<pT0>)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Induction regimen efficacy (DA-90 vs DAC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Salvage regimen efficacy (CLAG-M vs FLAG-IDA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve (AUC (0-∞))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve AUC (0-last)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: retinal vascular density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: retinal vascular perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Choroid thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mother-infant bond (MIB) scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline in skin wrinkles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in FAVK total score for peer related aggression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Safety of micro-laparoscopic versus laparoscopic gastric bypass
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Radiation Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with discordant results due to intercurrent disease
Endpoint domain: Adverse events/effects
Primary endpoint: Child's total distress score during the IV procedure
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Depression symptomatology
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline in the Neck Disability Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proteomic profile for tumor discrimination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Serum autotaxin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Positive Response on Columbia Suicide Severity Rating Scale (C-SSRS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevention of COVID-19 infection
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with Changed Reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Area Under The Concentration Curve (AUC 0-30mins) of Insulin Lispro
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mean Average Best Corrected Visual Acuity (BCVA) Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain measurement at 30 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drug Liking VAS maximum effect (Emax)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Apoptotic Index of the Highest Gleason Grade Malignant Epithelium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: improvement in Best Corrected Visual Acuity (BCVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pressure-pain threshold and tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ischemic pain threshold and tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ultrasound measurement of pressure in compartment in leg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of Coronary Artery Disease (CAD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline to Week 8 in WAIS-III Digit Span Subtest (Digits Forward)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change From Baseline to Week 8 in WAIS-III Digit Span Subtest (Digits Backward)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change From Baseline to Week 8 in WAIS-III Digit Symbol Coding Test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change From Baseline to Week 8 in Stroop Color-Word Test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change From Baseline to Week 8 in Trail Making Test Part A
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Histopathological findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ultra-structural findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of needle revolutions to achieve threshold torque
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median percentage prediction error of estimated propofol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes